What Are Johnson And Johnson Products？

Founded in 1886, Johnson &Johnson is the world's largest healthcare and consumer care products companywith diversified products. According to the results published by"Fortune" and "Business Weekly" in 1997, Johnson &Johnson's market value index ranked 20th in the world, and ranked among the topten most enviable companies in the United States, with a global turnover of275% in 1999. One hundred million U.S. dollars. Johnson & Johnson hasestablished more than 250 branches in 60 countries around the world, with about115,000 employees, and its products are sold in 175 countries and regions.

Johnson and Johnson productsinclude three categories, namely pharmaceutical products, targeting areasincluding: allergy and influenza/non-influenza, chronic bronchitis, digestivesystem treatment, scalp health treatment, skin symptom treatment,psychotherapy, pain symptom relief, bone Treatment, cancer treatment; medicalequipment, targeted areas include: women's health care, diabetes, minimallyinvasive surgery, wound closure, cardiovascular and cerebrovascular health,bone health, equipment disinfection, diagnostic products and services; personalcare products, targeted areas include: Baby health care series, adult skin careproducts series, women's health care products, vision care products, personalhealth care products and other series. The following highlights the Johnson andJohnson products for diseases.

Daratumumab

Daratumumab is a humanized,anti-CD38 IgG1 monoclonal antibody that binds to CD38 expressed by tumor cellsthrough complement-dependent cytotoxicity, antibody-dependent cell-mediatedcytotoxicity and antibody-dependent phagocytosis, as well as Fcγ receptors andother immune-related mechanisms induce tumor cell apoptosis.

As the first CD38 monoclonalantibody, daratumumab has two main mechanisms of action. On the one hand, itdirectly acts on myeloma cells and exerts immune-mediated activity. It is worthnoting that DARA is a CD38 protein with 42 different epitopes. The onlymonoclonal antibody with complement CDC activity. On the other hand,daratumumab regulates the immune microenvironment, thereby activating killer Tcells CD8+ and helper T cells CD4+, rapidly and lastingly eliminating CD38+immunosuppressive cells, continuously promoting myeloma cell death, andachieving deep and durable remission. Not only that, DARA can also enhance theeffect of a variety of anti-myeloma drugs, and it has a synergistic effect withbortezomib and lenalidomide, which has the potential to make patients developnew responses to their previously used drugs. In GEN501 In the SIRIUS study,patients with high bortezomib resistance were re-treated withbortezomib-containing regimens and observed clinical responses.

Whether the curative effect is goodor not can only be known by comparison. In 2015, a total of four new drugs formultiple myeloma were approved for marketing: Panobinostat, Ixazomib,daratumumab, and elotuzumab; among them, daratumumab All the way to upgrade tofight monsters, from third- and fourth-line drugs, to second-line drugs, andnow the first-line drugs have only been used for a few years, and its efficacyand safety are evident.

On July 5, 2019, the State DrugAdministration conditionally approved the import registration application ofdaratumumab injection for the single-agent treatment of adult patients withrelapsed and refractory multiple myeloma, including those who have received aprevious Patients with a proteasome inhibitor and an immunomodulator who haddisease progression on the last treatment.

Imbruvica

Imbruvica is the first once-daily,single-agent, oral Bruton's tyrosine kinase (BTK) inhibitor jointly developedand commercialized by Johnson & Johnson and Pharmacyclics, which inhibitsthe replication and metastasis of tumor cells by blocking BTK. to anticancereffect. Johnson & Johnson and Pharmacyclics announced on February 12 thatthe anticancer drug Imbruvica (ibrutinib capsules) was approved by the FDA forthe treatment of chronic lymphocytic leukemia (CLL) patients who have receivedat least one prior therapy. Imbruvica was approved by the FDA in November 2013for the treatment of patients with mantle cell lymphoma (MCL) who have receivedat least one prior treatment with lenalidomide or other drugs. Approval forboth indications is based on overall response rate (ORR) data, and data onimprovement in survival or disease-related symptoms have not been established.At the same time, Imbruvica is also one of the first drugs to be grantedbreakthrough therapy designation and approved by the FDA.

Whether in China or other countriesand regions, Johnson & Johnson has always put high-quality and safeproducts and caring for the health and well-being of consumers and patients asa commitment above all else. The quality of Johnson and Johnson products hasvery strict requirements, and there are global unified safety and qualitystandards. In short, as a major international brand, Johnson and Johnsonproducts are relatively safe and effective. When consumers buy Johnson andJohnson products, they don't have to worry too much about their safety.